Asher Bio, Alma, NeuExcells
Healthtech startup Oviva raises €67.7M funding; plans to grow its team to 800 employees by 2022-end
Berlin-based healthtech startup Oviva announced that it has raised $80M(€67.7M) in its Series C round of funding.
The round was co-led by Sofina and Temasek. Existing investors AlbionVC, Earlybird, Eight Roads Ventures, F-Prime Capital and MTIP, along with several angel investors, also participated.
With the proceeds from this round, the company plans to scale its technology and expand its team to 800 employees by the end of 2022.
Oviva empowers people to change their diet-related habits and thereby improve their long-term health and well-being.
Oviva’s helps treat people with diet-related diseases and helps prevent disease development through diet and lifestyle coaching, combining it with an intuitive app.
Healthtech startup Oviva raises €67.7M funding; plans to grow its team to 800 employees by 2022-end | Silicon Canals
Oviva announced that it has raised $80M(€67.7M) in its Series C round of funding.
Locate Bio Raises £10M in Funding
Locate Bio, a Nottingham, England, UK-based orthobiologics focused regenerative medicine company, raised £10m in equity funding.
The round, which brings the total funds raised by Locate Bio to over £18m, was co-led by existing shareholder Mercia Asset Management and new investor BGF.
The company intends to use the funds to further advance its proprietary pipeline of regenerative orthobiologics products towards patients, with key clinical and regulatory milestones expected to catalyze growth over the next two years.
Led by John von Benecke, CEO, Locate Bio is an orthobiologics company with a proprietary, regenerative medicine pipeline of orthobiologics products.
Locate Bio Raises £10M in Funding - FinSMEs
Locate Bio, a Nottingham, England, UK-based orthobiologics focused regenerative medicine company, raised £10m in equity funding
Asher Bio Raises $108M in Series B Funding
Biotherapeutics, a South San Francisco CA-based biotechnology company, raised $108M in Series B funding.
The round was led by Wellington Management Company LLP with participation from RA Capital Management, Janus Henderson Investors, Logos Capital, Marshall Wace, Alexandria Venture Investments, Third Rock Ventures, Invus, Boxer Capital of Tavistock Group and Mission BioCapital.
The company intends to use the funds to lead cis-targeted immunotherapy, AB248, through clinical proof-of-concept, while advancing a second program through investigational new drug (IND)-enabling studies and continuing to invest in its cis-targeting platform.
Led by Ivana Djuretic, Ph.D., Co-Founder and Chief Scientific Officer, and Craig Gibbs, Ph.D., Chief Executive Officer, Asher Biotherapeutics is a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases. The company aims to advance a portfolio of cis-targeted therapies derived from diverse cytokines and cell-types, each designed to address the challenge of pleiotropy that limits the efficacy and tolerability of many immunotherapies.
Asher Bio Raises $108M in Series B Funding - FinSMEs
Asher Biotherapeutics, a South San Francisco CA-based biotechnology company, raised $108M in Series B funding.
quip Raises $100M in Funding
quip, a NYC-based oral healthcare company with over 7.5 million users, raised $100m in growth funding.
Backers included Cowen Sustainable Investments. Artem Mariychin, Managing Director at CSI, will join the company’s board.
The company intends to use the funds to further scale its existing consumer packaged goods (CPG) business and accelerate the development of new verticals, innovations in professional services and global expansion.
Led by co-founder and CEO Simon Enever, quip provides personal oral care products and professional dental care services. The current personal care offerings include a wide selection of American Dental Association accepted (ADA seal) adult and kid electric toothbrushes, smart brushes, refillable floss pick and string, mouthwash and gum, all kept fresh with a refill delivery service.
quip Raises $100M in Funding - FinSMEs
quip, a NYC-based oral healthcare company with over 7.5 million users, raised $100m in growth funding
Disc Medicine Raises $90M in Series B Funding
Medicine, a Cambridge MA-based biotechnology company, raised $90M in Series B funding.
The round was led by OrbiMed with participation from new investors Arix Bioscience, Janus Henderson Investors, 5AM Ventures, Rock Springs Capital, Nantahala Capital Management, Willett Advisors, and Alexandria Venture Investments and existing investors Atlas Venture, Novo Holdings and Access Biotechnology.
Led by John Quisel, JD, PhD, Chief Executive Officer, Disc Medicine provides a clinical-stage biotechnology programs dedicated to the discovery and development of novel therapies for the treatment of serious and debilitating hematologic diseases.
The company intends to use the funds to develop its hematology pipeline of therapeutic candidates. It will also support a phase 2 clinical study of DISC-0974, an anti-hemojuvelin (HJV) monoclonal antibody designed to suppress hepcidin, to treat myelofibrosis patients with transfusion-dependent anemia. The company intends to expand clinical development of both programs and plans to initiate clinical studies in additional hematologic disorders.
Disc Medicine Raises $90M in Series B Funding - FinSMEs
Disc Medicine, a Cambridge MA-based biotechnology company, raised $90M in Series B funding.
Versanis Bio Raises $70M in Series A Financing
Versanis Bio, an Oakland, Calif.-based company established to discover and develop first-in-class medicines that address medical conditions prevalent in older adults, closed a $70m Series A financing.
The round was co-led by Atlas Venture and Medicxi with participation from Aditum Bio.
The company intends to use the funds to advance a comprehensive phase 2 clinical program to evaluate the potential of bimagrumab to help obese patients lose fat and achieve an improved body composition.
Led by Dr. Lloyd Klickstein, CEO, Versanis Bio is advancing bimagrumab, a human monoclonal antibody to the activin type II receptors that blocks the binding of ligands including activin A and myostatin.
Versanis Bio Raises $70M in Series A Financing - FinSMEs
Versanis Bio, an Oakland, Calif.-based company established to discover and develop first-in-class medicines that address medical conditions prevalent in older adults, closed a $70m Series A financing
ARS Pharmaceuticals Raises $55M in Series D Funding
ARS Pharmaceuticals, a San Diego CA-based pharmaceutical company, raised $55M in Series D funding.
The round was led by SR One with participation from RA Capital Management and Deerfield Management. As part of this funding, ARS appointed Rajeev Dadoo, Ph.D., managing partner of SR One, and Peter Kolchinsky, Ph.D., managing partner and founder of RA Capital to the board of directors.
Led by Richard Lowenthal, founder, chief executive officer and president, ARS Pharmaceuticals is developing Neffy™ (ARS-1), an intranasal epinephrine spray with absorption technology for patients and ones at-risk of severe allergic reactions to food, medications and insect bites that could lead to life-threatening anaphylaxis. ARS Pharmaceuticals is dedicated to empowering at-risk patients and caregivers to protect themselves from severe allergic reactions potentially leading to anaphylaxis.
ARS Pharmaceuticals Raises $55M in Series D Funding - FinSMEs
ARS Pharmaceutical, a San Diego CA-based pharmaceutical company, raised $55M in Series D funding.
Alma Raises $50M in Series C Funding
Alma, a New York-based mental health care network, raised $50M in Series C funding.
The round was led by Insight Partners, with participation from Optum Ventures, Tusk Venture Partners, Primary Venture Partners, Sound Ventures, BoxGroup and Rainfall Ventures.
The company intends to use the funds to expand operations and its business reach.
Led by Dr. Harry Ritter, founder and CEO, Laura Scott, Chief Operating Officer, and Kate Mellor, Vice President of Payer Strategy Alma is a membership-based network for mental health care providers to build and scale their practices. Its software platform offers insurance support, teletherapy software, automated billing, and scheduling tools to let therapists focus on providing care.
Alma Raises $50M in Series C Funding - FinSMEs
Alma, a New York-based company focused on network for mental health care, raised $50M in Series C funding.
CoRISMA Raises $27M in Series A Funding
CoRISMA, a New Haven CT-based stage medical device company, raised $27M in Series A funding.
The round was led by China Grand Pharmaceutical and Healthcare Holdings Limited, which will obtain approximately 22.2% equity interest in the company and broad commercial rights to the Greater China market.
The company intends to use the funds to accelerate development and expand availability of the CoRISMA cardiac treatment device.
Led by Mike Theran, Chief Executive Officer, and Pramod Bonde, CoRISMA has advanced a transcatheter that is implanted and features wirelessly powered mechanical circulation support. The company was founded in 2018, spun out of the Bonde Artificial Heart Lab at Yale University.
CoRISMA Raises $27M in Series A Funding - FinSMEs
CoRISMA, a New Haven CT-based stage medical device company, raised $27M in Series A funding.
Ellipsis Health Raises $26M in Series A Funding
Ellipsis Health, a San Francisco, CA-based developer of a voice vital sign to quantify and manage depression and anxiety at scale, raised $26m in Series A funding.
The round, which brought total funding to $31m, was led by SJF Ventures with participation from AblePartners, Akhil Paul at Caparo Group, etc.
The company intends to use the funds to:
continue to grow its customer base,
expand global partnerships,
build a multidisciplinary team,
research, and develop new voice-based technology,
expand its voice vital sign to address the mental health of children and adolescents.
Led by Mainul I Mondal, Founder and CEO, Ellipsis Health has pioneered an artificial intelligence-powered, speech-based vital sign to quantify and manage stress, depression, and anxiety symptoms at scale.
Ellipsis Health Raises $26M in Series A Funding - FinSMEs
Ellipsis Health, a San Francisco, CA-based developer of a voice vital sign to quantify and manage depression and anxiety at scale, raised $26m in Series A funding
Plantible Raises $21.5M in Series A Funding
Plantible, a San Diego CA-based food-tech/biotech company, raised $21.5M in Series A funding.
The round was led by Astanor Ventures with participation from Piva Capital, CJ CheilJedang, Good Friends, etc.
The company intends to use the funds to build its first commercial facility to launch and commercialize its product in 2022.
Founded in 2018 by Tony Martens and Maurits van de Ven, Plantible has developed a vertically integrated agricultural platform to produce Rubi Protein(™) from Lemna, more commonly known as duckweed. The natural, plant-based protein emulates the functional characteristics of widely used animal-based proteins and enables food companies to match the taste and texture of animal-based products with more sustainable plant-based ingredients.
Plantible Raises $21.5M in Series A Funding - FinSMEs
Plantible, a San Diego CA-based Food-tech company, raised $21.5M in Series A funding.
Centaur Labs Raises $15M in Funding
Centaur Labs, a Boston, MA-based medical data labeling company, raised $15m in funding.
The Series A round was led by Matrix Partners with participation from other funds including Accel, Global Founders Capital, Susa Ventures, Y Combinator, and individual investors including John Capodilupo (founder and CTO of WHOOP), Tom Lee (founder of One Medical), and Elliot Cohen (founder and CPO of PillPack).
The company intends to use the funds for the expansion of its global network of labelers and accelerate product development and hiring.
Co-founded in 2017 by Tom Gellatly, VP of Engineering, Erik Duhaime, CEO, and Zach Rausnitz, CTO, Centaur Labs Founded in 2017, Centaur Labs is advancing medical AI through accurate medical data labeling. Its network of experts provides labels on a wide range of data formats, including medical images (X-ray, CT/MR, dermatology, ophthalmology, pathology), videos (surgical videos, ultrasound), text (scientific text, medical notes), and audio recordings (heart and lung sounds).
Centaur Labs Raises $15M in Funding - FinSMEs
Centaur Labs, a Boston, MA-based medical data labeling company, raised $15m in funding
Onkos Surgical Raises $15M in Series C Funding
Parsippany, NJ-based provider of surgical solutions for musculoskeletal oncology and orthopaedics, raised $15M in Series C funding.
The backers – part of an existing investor syndicate – were not disclosed.
The company intends to use the funds to accelerate research and development pipeline, expand its commercial footprint, and evolve its manufacturing capabilities.
Led by Co-Founder and CEO Patrick Treacy, Onkos Surgical is a provider of solutions for musculoskeletal oncology and complex orthopaedic procedures. Its personalized approach supports improved patient outcomes and experiences using the latest innovations in virtual surgical planning, 3D modeling and printing, implant design, and workflow optimization.
Onkos Surgical Raises $15M in Series C Funding - FinSMEs
Onkos Surgical, a Parsippany NJ-based company focused on musculoskeletal oncology and orthopaedic procedures, raised $15M in Series C funding.
NeuExcell Therapeutics Raises Over $10M in Series Pre-A Funding
NeuExcell Therapeutics, a State College, Pa.- and Shanghai, China-based gene therapy company focusing on neurodegenerative diseases, raised $10+m in Series Pre-A financing.
The round was led by Co-Win Ventures, joined by other institutional investors YuanBio, Oriza Seed, Tsingyuan and InnoAngel.
The company intends to use the funds to continue to expand its development efforts.
Led by Peter Tombros, Board Chair, and Professor Gong Chen, co-founder and chief scientific advisor, NeuExcell is an early-stage gene technology company which aims to improve the lives of patients suffering from neurodegenerative diseases and CNS injuries. Based upon the scientific work of Prof. Gong Chen, the company has developed neural repair technology through astrocyte-to-neuron conversion in vivo by introducing neural transcription factor(s) through adeno-associated virus (AAV)-based gene therapy.
